{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:01:58Z","timestamp":1771236118840,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2016.62","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T16:14:36Z","timestamp":1469808876000},"page":"e450-e450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Thrombotic microangiopathy during carfilzomib use: case series in Singapore"],"prefix":"10.1038","volume":"6","author":[{"given":"Y","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S F","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Phipps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y S","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N F","family":"Grigoropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Surendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E M","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y T","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W J","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S K","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,29]]},"reference":[{"key":"BFbcj201662_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2217\/fon.11.42","volume":"7","author":"ML Khan","year":"2011","unstructured":"Khan ML, Stewart AK. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol. 2011; 7: 607\u201312. Available from http:\/\/www.futuremedicine.com\/doi\/abs\/10.2217\/fon.11.42.","journal-title":"Future Oncol"},{"key":"BFbcj201662_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142\u2013152.","journal-title":"N Engl J Med"},{"key":"BFbcj201662_CR3","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","volume":"19","author":"TM Herndon","year":"2013","unstructured":"Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD et al. US Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19: 4559\u20134563.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201662_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98: 1753\u20131761.","journal-title":"Haematologica"},{"key":"BFbcj201662_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-2369-15-156","volume":"15","author":"L Hobeika","year":"2014","unstructured":"Hobeika L, Self SE, Velez JCQ . Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol 2014; 15: 156.","journal-title":"BMC Nephrol"},{"key":"BFbcj201662_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ckj\/sfv059","volume":"8","author":"A Lodhi","year":"2015","unstructured":"Lodhi A, Kumar A, Saqlain MU, Suneja M . Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J 2015; 8: 632\u2013636.","journal-title":"Clin Kidney J"},{"key":"BFbcj201662_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","volume":"124","author":"N Lendvai","year":"2014","unstructured":"Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM et al. A phase 2 single-center study of carfilzomib 56\u2009mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood 2014; 124: 899\u2013906.","journal-title":"Blood"},{"key":"BFbcj201662_CR8","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","volume":"15","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009; 15: 7085\u20137091.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201662_CR9","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","volume":"18","author":"M Alsina","year":"2012","unstructured":"Alsina M, Trudel S, Furman RR, Rosen PJ, O\u2019Connor OA, Comenzo RL et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012; 18: 4830\u20134840.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201662_CR10","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1182\/blood-2015-02-626168","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau P, Kolb B, Attal M, Caillot D, Benboubker L, Tiab M et al. Phase 1\/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood 2015; 125: 3100\u20133104.","journal-title":"Blood"},{"key":"BFbcj201662_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129\u20131136.","journal-title":"N Engl J Med"},{"key":"BFbcj201662_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27\u201338.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201662.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201662","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201662.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T09:07:07Z","timestamp":1672823227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,29]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"alternative-id":["BFbcj201662"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.62","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,29]]},"assertion":[{"value":"29 July 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SKG has received research funding from Amgen. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}